Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289262 | 1.00 | NOD1 (0.40) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL11305652 | 0.83 | GRIK1 (0.40) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL19859237 | 0.81 | NOD1 (0.47) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL9634474 | 0.80 | NOD1 (0.49) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL9634471 | 0.80 | NOD1 (0.49) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL8934208 | 0.79 | GPR84 (0.38) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL8934205 | 0.79 | GPR84 (0.38) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL341674 | 0.79 | NOD1 (0.51) | NOD1GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL11308884 | 0.79 | GRIK1 (0.42) | GRIK1GRIK2SLC1A2SLC1A1SLC6A5 | |
| SCHEMBL1031164 | 0.79 | NOD1 (0.51) | NOD1GRIK1GRIK2SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220211820-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | UNIV CASE WESTERN RESERVE (US) | 2022-07-07 | — | — | US | disclosed |
| US-11229685-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-25 | — | — | US | disclosed |
| US-10548860-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190192452-A1 | HIF-1 MODULATOR PAINT FORMULATION AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-06-27 | — | — | US | disclosed |
| US-10220009-B2 | HIF-1 modulator paint formulation and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-03-05 | — | — | US | disclosed |
| US-9763899-B2 | Iron chelators and use thereof for reducing transplant failure during rejection episodes | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170252310-A9 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-09-07 | — | — | US | disclosed |
| US-9603839-B2 | Thioredoxin protein inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160184244-A1 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes | UNIV LELAND STANFORD JUNIOR (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2014120774-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014100233-A1 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE DURING REJECTION EPISODES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014036414-A2 | IRON CHELATORS AND USE THEREOF FOR REDUCING TRANSPLANT FAILURE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-03-06 | — | — | WO | disclosed |
| WO-2013158892-A1 | THIOREDOXIN PROTEIN INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-10-24 | — | — | WO | disclosed |
| EP-2412371-A1 | Compositions comprising iron chelators (deferiprone/deferasirox) for use in the treatment of mucormycosis and other fungal diseases | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110003013-A1 | METHOD OF INCREASING METABOLISM | GARVAN INSTITUTE OF MEDICAL RESEARCH | 2011-01-06 | — | — | US | disclosed |
| US-20100129434-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2009086592-A1 | METHOD OF INCREASING METABOLISM | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2009-07-16 | — | — | WO | disclosed |
| EP-2043636-A2 | (COMBI) COMPOSITIONS FOR THE TREATMENT OF MUCORMYCOSIS COMPRISING IRON CHELATOR AND ANTIFUNGAL AGENT | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008537-A2 | COMBI) COMPOSITIONS FOR THE TREATMENT OF MUCORMYCOSIS. COMPRISING IRON CHELATOR AND ANTIFUNGAL AGENT | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003013-A1 | METHOD OF INCREASING METABOLISM | HIF1A, HIF1AN, PC | NOD1 2758/4885GRIK1 2433/4885GRIK2 2243/4885 |
| US-11229685-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | NOD1 1891/4885GRIK1 3526/4885GRIK2 3268/4885 |
| US-20220211820-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | SLC40A1, SLC30A6, SLC30A7 | NOD1 1891/4885GRIK1 3526/4885GRIK2 3268/4885 |
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | NOD1 1891/4885GRIK1 3526/4885GRIK2 3268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.